Literature DB >> 32121639

Heterogeneity of Circulating Tumor Cells in Breast Cancer: Identifying Metastatic Seeds.

Maxim E Menyailo1, Maria S Tretyakova1, Evgeny V Denisov1.   

Abstract

Metastasis being the main cause of breast cancer (BC) mortality represents the complex and multistage process. The entrance of tumor cells into the blood vessels and the appearance of circulating tumor cells (CTCs) seeding and colonizing distant tissues and organs are one of the key stages in the metastatic cascade. Like the primary tumor, CTCs are extremely heterogeneous and presented by clusters and individual cells which consist of phenotypically and genetically distinct subpopulations. However, among this diversity, only a small number of CTCs is able to survive in the bloodstream and to form metastases. The identification of the metastasis-initiating CTCs is believed to be a critical issue in developing therapeutic strategies against metastatic disease. In this review, we summarize the available literature addressing morphological, phenotypic and genetic heterogeneity of CTCs and the molecular makeup of specific subpopulations associated with BC metastasis. Special attention is paid to the need for in vitro and in vivo studies to confirm the tumorigenic and metastatic potential of metastasis-associating CTCs. Finally, we consider treatment approaches that could be effective to eradicate metastatic CTCs and to prevent metastasis.

Entities:  

Keywords:  breast cancer; circulating tumor cells; heterogeneity; metastasis

Year:  2020        PMID: 32121639     DOI: 10.3390/ijms21051696

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  7 in total

1.  Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse.

Authors:  Oliver Hoffmann; Sebastian Wormland; Ann-Kathrin Bittner; Monika Collenburg; Peter A Horn; Rainer Kimmig; Sabine Kasimir-Bauer; Vera Rebmann
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-02       Impact factor: 4.553

2.  Association of early changes of circulating cancer stem-like cells with survival among patients with metastatic breast cancer.

Authors:  Pei-Hung Chang; Chun-Hui Lee; Tyler Min-Hsien Wu; Kun-Yun Yeh; Hung-Ming Wang; Wen-Kuan Huang; Sheng-Chieh Chan; Wen-Chi Chou; Feng-Che Kuan; Hsuan-Chih Kuo; Yung-Chia Kuo; Ching-Chih Hu; Jason Chia-Hsun Hsieh
Journal:  Ther Adv Med Oncol       Date:  2022-07-15       Impact factor: 5.485

3.  Regulation of Tissue Factor by CD44 Supports Coagulant Activity in Breast Tumor Cells.

Authors:  Amélie V Villard; Anthony Genna; Justine Lambert; Marianna Volpert; Agnès Noël; Brett Hollier; Myriam Polette; Aline M Vanwynsberghe; Christine Gilles
Journal:  Cancers (Basel)       Date:  2022-07-05       Impact factor: 6.575

Review 4.  Reporters of Cancer Stem Cells as a Tool for Drug Discovery.

Authors:  Amrutha Mohan; Reshma Raj R; Gayathri Mohan; Padmaja K P; Tessy Thomas Maliekal
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

Review 5.  The Landscape of PDK1 in Breast Cancer.

Authors:  Na Wang; Jianjiang Fu; Zhihua Li; Ningni Jiang; Yanhong Chen; Juan Peng
Journal:  Cancers (Basel)       Date:  2022-02-05       Impact factor: 6.639

6.  Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant (SNV) Single Cell Analysis.

Authors:  Tania Rossi; Davide Angeli; Michela Tebaldi; Pietro Fici; Elisabetta Rossi; Andrea Rocca; Michela Palleschi; Roberta Maltoni; Giovanni Martinelli; Francesco Fabbri; Giulia Gallerani
Journal:  Cancers (Basel)       Date:  2022-08-14       Impact factor: 6.575

Review 7.  Metastasis Prevention: Focus on Metastatic Circulating Tumor Cells.

Authors:  Maxim E Menyailo; Ustinia A Bokova; Elena E Ivanyuk; Anna A Khozyainova; Evgeny V Denisov
Journal:  Mol Diagn Ther       Date:  2021-07-21       Impact factor: 4.074

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.